Amgen Inc., of Thousand Oaks, Calif., and UCB SA, of Brussels, Belgium, disclosed detailed results from the phase III Arch study showing that 12 months of sclerostin binder Evenity (romosozumab) followed by alendronate was superior in reducing new vertebral, clinical, nonvertebral and hip fracture risk in postmenopausal women with osteoporosis at high risk for fracture, compared to alendronate alone.